Back to Search
Start Over
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.
- Source :
-
Trends in pharmacological sciences [Trends Pharmacol Sci] 2010 Aug; Vol. 31 (8), pp. 381-90. Date of Electronic Publication: 2010 Jun 25. - Publication Year :
- 2010
-
Abstract
- Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia. While often effective at ameliorating psychosis, these drugs are largely ineffective at treating negative and cognitive symptoms. Increasing attention is being focused on the complex genetics of the illness and the signaling pathways implicated in its pathophysiology. We review targeted approaches for pharmacotherapy involving the glutamatergic, GABAergic and cholinergic pathways. We also describe several of the major genetic findings that identify signaling pathways representing potential targets for novel pharmacological intervention. These include genes in the 22q11 locus, DISC1, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway.<br /> (2010 Elsevier Ltd. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-3735
- Volume :
- 31
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Trends in pharmacological sciences
- Publication Type :
- Academic Journal
- Accession number :
- 20579747
- Full Text :
- https://doi.org/10.1016/j.tips.2010.05.004